載入...
Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma: A randomized phase III Intergroup study by EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-26033)
BACKGROUND: Outcome of low-grade glioma (LGG, WHO grade II) is highly variable reflecting molecular heterogeneity of the disease. We compared two different single modality treatment strategies: standard radiotherapy (RT) versus primary temozolomide (TMZ) chemotherapy with the aim of tailoring treatm...
Na minha lista:
| 發表在: | Lancet Oncol |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
2016
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5124485/ https://ncbi.nlm.nih.gov/pubmed/27686946 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(16)30313-8 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|